Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia 19Leukemia, Myeloid, Chronic-Phase 16Breast Neoplasms 11Neoplasm Metastasis 10Leukemia, Myeloid, Acute 8Blast Crisis 8Prostatic Neoplasms 7Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Recurrence 5Pancreatic Neoplasms 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Lymphocytic, Chronic, B-Cell 5Melanoma 4Gliosarcoma 4Glioblastoma 4Rectal Neoplasms 3Philadelphia Chromosome 3Lung Neoplasms 3Glioma 3Gastrointestinal Stromal Tumors 3Colorectal Neoplasms 3Colonic Neoplasms 3Brain Neoplasms 3Sarcoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2

Interventions

Imatinib Mesylate 3nilotinib 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Dasatinib 1Cytarabine 1Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hypereosinophilic Syndrome × Dasatinib × Clear all
NCT00255346 2025-12-30

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 13 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Myelodysplastic Syndromes, Polycythemia Vera, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡